09 mayo 2011
El departamemnto de análisis de Renta 4 recomienda tomar posiciones en Zeltia si los títulos del valor cierran por encima de los 3,2 euros .
ZELTIA pierde la directriz alcista que guiaba las alzas desde finales de 2010, según señalan desde Renta 4 y lo hace con un gap bajista en 2,8 € "que hará de resistencia en los rebotes." A medio plazo "será necesaria una superación de la franja de 3,2€ (soporte durante 2010 y que ahora representa obstáculo a las alzas) para hablar de un cambio de tendencia."
Safety Profile of Yondelis in Combination With Liposomal Pegylated Doxorrubicin in Relapsed Ovarian Carcinoma: Considerations for Optimal Management .
International Journal of Gynecological Cancer .May 2011 - Volume 21 - Issue 10 - pp S6-S8 .
Martín, Antonio González MD . Medical Oncology Department, Cancer Center M.D. Anderson International, Madrid, Spain .
Abstract :
The toxicity profile of trabectedin in the OVA-301 trial, that combined trabectedin with pegylated liposomal doxorubicin for the treatment of patients with ovarian cancer, has shown to be predictable and manageable. No unexpected toxicities were found, with neutropenia and transient increase in transaminases as the most common adverse events reported. The elevation in transaminases appeared early and generally decreased in incidence and intensity over subsequent cycles, with no major clinical consequences. A similar safety profile was seen in the analysis of the older patients in the trial. There were no detrimental effects in quality of life with the combination. Moreover, the Global Health Status score was better for the combination arm in those patients with a PFI of 6 to 12 months that were in response after 5 cycles. Trabectedin with pegylated liposomal doxorubicin is not associated with cumulative end-organ toxicities (renal, cardiac, or neurological toxicities). The toxicity profile is different from other second-line strategies without the presence of inconvenient side effects, such as alopecia, hypersensitivity reactions, hand-foot syndrome, or mucositis.
Copyright © 2011 by IGCS and ESGO
Martín, Antonio González MD . Medical Oncology Department, Cancer Center M.D. Anderson International, Madrid, Spain .
Abstract :
The toxicity profile of trabectedin in the OVA-301 trial, that combined trabectedin with pegylated liposomal doxorubicin for the treatment of patients with ovarian cancer, has shown to be predictable and manageable. No unexpected toxicities were found, with neutropenia and transient increase in transaminases as the most common adverse events reported. The elevation in transaminases appeared early and generally decreased in incidence and intensity over subsequent cycles, with no major clinical consequences. A similar safety profile was seen in the analysis of the older patients in the trial. There were no detrimental effects in quality of life with the combination. Moreover, the Global Health Status score was better for the combination arm in those patients with a PFI of 6 to 12 months that were in response after 5 cycles. Trabectedin with pegylated liposomal doxorubicin is not associated with cumulative end-organ toxicities (renal, cardiac, or neurological toxicities). The toxicity profile is different from other second-line strategies without the presence of inconvenient side effects, such as alopecia, hypersensitivity reactions, hand-foot syndrome, or mucositis.
Copyright © 2011 by IGCS and ESGO